Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis

Hosseini, Hamid; Nejabat, Mahmood; Mehryar, M; Yazdchi, Taher; Sedaghat, Ahad; Noori, Farajollah

doi:10.1111/j.1442-9071.2007.01572.x

Cited by 71 publications

(51 citation statements)

References 22 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A diminuição da extensão dos vasos comprova o efeito esperado da droga nas queimaduras químicas e está de acordo com os dados encontrados na literatura recente (20)(21) . Os estudos também mostram que o efeito da droga é maior se esta é aplicada simultaneamente com a cauterização química.…”

Section: Discussionunclassified

Ação do bevacizumabe subconjuntival na neovascularização e re-epitelização corneana 25 dias após queimadura química

Mello¹,

Lupion²,

Oliveira³

et al. 2011

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Nota Editorial: Depois de concluída a análise do artigo sob sigilo editorial e com a anuência do Dr. Vinícius Coral Ghanem e Procópio Miguel dos Santos sobre a divulgação de seu nome como revisor, agradecemos sua participação neste processo.Ação do bevacizumabe subconjuntival na neovascularização e re-epitelização corneana 25 dias após queimadura química ABSTRACT Purposes:To evaluate the effect of subconjunctival bevacizumab in an experimental model of neovascularization in rabbit cornea. Determine its effect on vessels extension, inflammation, epithelialization of the cornea and whether the evaluation method used is appropriate to compare neovascular models. Methods: Experimental, prospective, randomized, blinded study in twenty rabbits subjected to chemical trauma with sodium hydroxide at 1N divided into two groups. The study group received subconjunctival injection of 0.15 ml (3.75 mg) of bevacizumab and was compared with the control group that received subconjunctival injection of 0.15 ml saline solution. After 25 days, digital photographic analysis was performed to assess the vessel's extension and inflammation/diameter according to pre-established criteria. Histopathology of the cornea, which evaluated the state of the epithelium and the number of polymorphonuclear cells was also studied. Results:The length of the neovessels was greater in the control group compared to the study group (P=<0.001). There was no difference in inflammation/vessel diameter between groups. Histopathology analysis showed that there was no difference between groups for the variables state of the epithelium and number of polymorphonuclear cells. The concordance analysis for the variable extension of the vessels and the variable inflammation/vessel diameter was estimated with Kappa coefficients of 0.705 and 0.500 respectively, indicating a good level of agreement in different evaluations and validating the method. Conclusions:The experimental model is adequate and can be reproduced to evaluate other drugs in the cornea. Bevacizumab inhibit the neovessels' growth but was not effective in preventing the inflammatory response. The drug did not delay the reepithelialization of the cornea.

show abstract

Section: Discussionunclassified

Ação do bevacizumabe subconjuntival na neovascularização e re-epitelização corneana 25 dias após queimadura química

Mello¹,

Lupion²,

Oliveira³

et al. 2011

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

show abstract

“…tavflanlarda NaOH ile oluflturulan korneal neovaskülari-zasyon modelinde subkonjonktival bevacizumab›n etkinli¤ini de¤erlendirmek için iki grup oluflturmufl; birinci gruba alkali yan›¤› takiben hemen 2,5 mg tek doz subkonjonktival bevacizumab, ikinci gruba ise 2,5 mg tek doz subkonjonktival dengeli tuz solüsyonu uygulam›flt›r. Üç haftal›k deney süresinin sonunda tedavi grubunda kontrol grubuna göre korneal neovaskülarizasyonda %32 azalma saptanm›fl ve meydana gelen en uzun damar boyu kontrol grubuna göre daha k›sa bulunmufltur (19). Bizim ça-l›flmam›zda ise; neovaskülarizasyon oran›nda azalma subkonjonktival bevacizumab grubunda %27, topikal bevacizumab grubunda ise %33 olup meydana gelen en uzun damar boyu da kontrol grubuna göre daha k›sa olarak bulundu.…”

Section: Tart›flmaunclassified

Alkali Yanığına Bağlı Gelişen Korneal Anjiogenez Modelinde Topikal, Subkonjonktival Bevacizumab ve Florometolon Asetatın Topikal Uygulanması - Özgün Araştırma

Topalkara¹,

Toker²,

Dursun³

et al. 2010

tjo

View full text Add to dashboard Cite

ÖzetAmaç: Alkali yan›¤a ba¤l› geliflen korneal anjiogenez modelinde kornea neovaskülarizasyonu üzerine bevacizumab›n etkisini araflt›rmak. Gereç ve Yöntem: Çal›flmada 24 adet Wistar-Albino cinsi rat kullan›ld›. Kornealarda kimyasal koterizasyonu takiben ratlar tesadüfi olarak 4 gruba ayr›ld›. Grup 1'e (kontrol grubu) suni gözyafl› günde iki kez, grup 2'ye topikal florometolon asetat günde iki kez, Grup 3'e subkonjonktival bevacizumab 2,5 mg olarak tek doz, grup 4'e ise topikal bevacizumab günde iki kez 5 mg/ml konsantrasyonunda uyguland›. Üç hafta sonra rat kornealar› biyomikroskopla muayene edildi ve kornea foto¤raflar› çekilip denekler sakrifiye edildi. Neovaskülarize alan oran›, geliflen en uzun damar›n boyu, korneal ödem ve opasite skoru de¤erlendirildi. Sonuçlar: Dijital foto¤raflar analiz edildi¤inde korneal neovaskülarizasyon, geliflen en uzun damar›n boyu, korneal ödem ve opasite skorunun her 3 grupta kontrol grubundan daha düflük oldu¤u görüldü (p<0,05). Korneal neovaskülarizasyon Grup 3 ve 4'de, grup 2'den daha düflüktü (p=0,035, p=0,027). Topikal ve subkonjonktival bevacizumab gruplar› aras›nda korneal neovaskülarizasyon, korneal ödem ve opasite skoru aç›s›ndan anlaml› bir fark saptanmad›. Bununla birlikte geliflen en uzun damar›n boyu topikal bevacizumab grubunda anlaml› olarak daha düflük bulundu (p=0,029). Material and Method: Twenty-four Wistar albino rats were used in our study. After chemical cauterization of the cornea, the rats were divided randomly into four groups. Group 1 (control group) received artificial tears twice a day, group 2 received topical fluorometholone acetate twice a day, in group 3, a single dose of bevacizumab (2.5 mg) was administered by a subconjunctival injection, and group 4 received topical bevacizumab 5mg/ml twice a day. Three weeks later, the rat corneas were evaluated by slit-lamp biomicroscopy and corneal photographs were taken with a digital camera, followed by sacrifice of the subjects. The proportional area of vascularized cornea, length of the longest neovascular sprout, corneal oedema and corneal opacity score were assessed. Result: The analysis of digital photographs showed less corneal neovascularization, corneal oedema, corneal opacity score and shorter length of the longest neovascular sprout in the three drug groups than in the control one (p<0.05). The area of corneal neovascularization in groups 3 and 4 was less than in group 2 (p=0.035 and p=0.027, respectively). Corneal neovascularization, corneal oedema and corneal opacity did not differ significantly between the subconjunctival and topical bevacizumab groups. However, statistically significant decrease was observed in the length of the longest neovascular sprout in the topical bevacizumab group (p=0.029). Discussion: Subconjunctival/topical bevacizumab treatment is an effective method in reducing corneal neovascularization. However, we observed that topical bevacizumab is more efficient than subconjunctival bevacizumab and fluorometholone acetate in preventing corneal neovascularization. (Turk J Oph...

show abstract

“…The decrease in vascularisation is less when bevacizumab is administered days or weeks after chemical cauterisation. 1,2 In the suture-induced model subconjunctival bevacizumab administration one week after suture insertion in the peripheral cornea decreased sutureinduced corneal vascularisation in rabbits. 3 In several small series involving patients with corneal vascularisation due to Stevens-Johnson syndrome, corneal graft failure and limbal stem cell deficiency, bevacizumab (25 mg/mL) eye-drops were applied four to five times daily for up to six months.…”

Section: Avastin Treatment For Corneal Neovascularisationmentioning

confidence: 99%

“…2 This randomised, double-masked and placebo-controlled study involved 76 female soft contact lens wearers, who were treated for six months with either EPO or placebo (olive oil). The EPO group showed a significant improvement in the symptom of 'dryness' at three and six months (p < 0.01) and also a significant improvement in overall lens comfort at six months (p < 0.01).…”

Section: Essential Fatty Acids For Dry Eye: Evidence Base Increasesmentioning

confidence: 99%

Ocular therapeutics

Albietz¹,

Napper²

2008

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Adherence in glaucomaCorrect use of medications has always been a problem, especially in chronic diseases. A new study using electronic monitoring of drug-bottle opening as an objective measurement of adherence in medical glaucoma management has confirmed the already widely accepted clinical impression that more complex glaucoma topical medication dosing regimens result in poorer adherence. Previously the term 'compliance' was used but 'adherence' is now considered a more appropriate term. Two populations of primary open angle glaucoma subjects were examined: those using monotherapy (once-daily prostaglandin analogues n = 31) and those requiring an adjunctive medicine to the prostaglandin analogue (two-drug group n = 31). The main outcome measures were dosing errors (number of underadherence or over-adherence events) and coverage (proportion of pharmacologic duration covered by dosing) relative to the prescribed regimen. Adherence to the prostaglandin once daily was good in both groups by all measures (less than 10 per cent of subjects with more than five dosing errors and mean coverage of 97.2 Ϯ 6.1 per cent). Adherence to the second medication in the two-drug group was poorer (37 per cent of subjects with more than five dosing errors and mean coverage of 85.6 Ϯ 12.6 per cent). For the subjects using beta-blockers, 24.8 Ϯ 18.4 per cent of doses were taken at less than 10-hour intervals (over-adherence).Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: Objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144: 533-540. Topical insulin improves corneal healing in diabetesCorneal epithelial healing can be a significant problem among diabetic patients. A recent study using a rat model with diabetes mellitus has shown that topical application of insulin normalised delayed corneal wound healing. The method involved creating a five-millimetre corneal abrasion, which was treated topically for seven days (four times daily) with 1, 2, or 5 U of insulin or with sterile vehicle.After seven days, residual corneal epithelial defects of rats with diabetes receiving the sterile vehicle were approximately 35 per cent larger than in healthy (nondiabetic) rats receiving the sterile vehicle. Diabetic rats receiving topical insulin had wounds ranging from 19 to 60 per cent smaller than diabetic rats not receiving topical insulin, similar to wound sizes in healthy rats. Topical insulin had no effect on re-epithelialisation of corneal wounds in healthy rats, corneal thickness, intraocular pressure or serum glucose level. The corneal sensitivity of diabetic rats was markedly reduced from healthy rats but rats with diabetes given insulin had corneal sensitivity values comparable to the healthy rats. DNA synthesis in the corneal epithelium was decreased in rats with diabetes but was comparable to that in healthy rats after they received topical insulin. Apoptosis and necrosis levels were similar in all healthy rats, diabetic rats treated with insulin and untreated diabetic...

show abstract

Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis

Abstract: Local injection of bevacizumab has a significant effect on inhibition of alkali burn-induced corneal neovascularization. This shows the potential value of bevacizumab in the treatment of corneal neovascularization.

Cited by 71 publications

References 22 publications

Ação do bevacizumabe subconjuntival na neovascularização e re-epitelização corneana 25 dias após queimadura química

Ação do bevacizumabe subconjuntival na neovascularização e re-epitelização corneana 25 dias após queimadura química

Alkali Yanığına Bağlı Gelişen Korneal Anjiogenez Modelinde Topikal, Subkonjonktival Bevacizumab ve Florometolon Asetatın Topikal Uygulanması - Özgün Araştırma

Ocular therapeutics

Contact Info

Product

Resources

About